Document headings vary by document type but may contain
                    the following: the agency or agencies that issued and signed a document
the number of the CFR title and the number of each part
                      the document amends, proposes to amend, or is directly
                      related to
the agency docket number / agency internal file number
the RIN which identifies each regulatory action listed in
                      the Unified Agenda of Federal Regulatory and Deregulatory
                      Actions See the
                    Document Drafting Handbook
                    for more details.
 Department of Health and Human Services Food and Drug Administration [Docket No. FDA-2012-N-0280]
 AGENCY: Food and Drug Administration, HHS.
 ACTION: Notice.
 SUMMARY: The Food and Drug Administration (FDA, Agency, or we) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.
 DATES: Submit written comments (including recommendations) on the collection of information by April 29, 2022.
 ADDRESSES: To ensure that comments on the information collection are received, OMB recommends that written comments be submitted to 
                        *https://www.reginfo.gov/​public/​do/​PRAMain.*
                         Find this particular information collection by selecting “Currently under Review—Open for Public Comments” or by using the search function. The OMB control number for this information collection is 0910-0396. Also include the FDA docket number found in brackets in the heading of this document.
 FOR FURTHER INFORMATION CONTACT: Amber Sanford, Office of Operations, Food and Drug Administration, Three White Flint North, 10A-12M, 11601 Landsdown St., North Bethesda, MD 20852, 301-796-8867, 
                        *PRAStaff@fda.hhs.gov.*


SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance. Financial Disclosure by Clinical Investigators OMB Control Number 0910-0396—Extension Respondents to this collection are sponsors of marketing applications that contain clinical data from studies covered by the regulations. These sponsors represent pharmaceutical, biologic, and medical device firms. Respondents are also clinical investigators who provide financial information to the sponsors of marketing applications. In the 
                    **Federal Register**
                     of December 2, 2021 (86 FR 68500), FDA published a 60-day notice requesting public comment on the proposed collection of information. Although one comment was received, it was not responsive to the four collection of information topics solicited. Table 1 shows information that is the basis of the estimated number of respondents in tables 2 through 4. Table 1—Estimated Number of Applications, Clinical Trials, and Investigators Subject to the Regulation by Type of Application 1
Application type
Total
                             number of 
                             applications
Number of
                             applications 
                             affected
Number of
                             trials
Number of
                             investigatorsDrugs:New drug application (NDA), new molecular entity (NME)
55
55
3 to 10
3 to 100.NDA non-NME
78
37
3 to 10
3 to 100.NDA efficacy supplement
196
119
1 to 3
10 to 30.Abbreviated new drug application (ANDA)
821
1
1.1
2.ANDA supplement
10,894
1
1
2.CBER Biologics:Biologics license application (BLA)
10
10
3 to 10
3 to 100.BLA efficacy supplement
30
30
1 to 3
10 to 30.CDER Biologics:( print page 18372)BLAs
25
25
3 to 10
3 to 100.BLA efficacy supplements
102
65
1 to 3
10 to 30.Medical Devices:Premarket approval (PMA)
39
39
1 to 31
10 to 20.PMA supplement
29
29
1 to 3
3 to 10.Reclassification devices
0
0
0
0.510(k)
3,947
247
1
3 to 10.De Novo requests
63
57
1 to 3
10 to 20.1
                         Source: Agency estimates.
 FDA estimates the burden of this collection of information as follows: Reporting Burden Under § 54.4(a) (21 CFR 54.4(a)), applicants submitting an application that relies on clinical studies must submit a complete list of clinical investigators who participated in a covered clinical study, and must either certify to the absence of certain financial arrangements with clinical investigators (Form FDA 3454) or, under § 54.4(a)(3), disclose to FDA the nature of those arrangements and the steps taken by the applicant or sponsor to minimize the potential for bias (Form FDA 3455). FDA estimates that almost all applicants submit a certification statement under § 54.4(a)(1) and (2). Preparation of the statement using Form FDA 3454 should require no more than 1 hour per study. The number of respondents is based on the estimated number of affected applications. When certification is not possible and disclosure is made using Form FDA 3455, the applicant must describe, under § 54.4(a)(3), the financial arrangements or interests and the steps that were taken to minimize the potential for bias in the affected study. As the applicant would be fully aware of those arrangements and the steps taken to address them, describing them will be straightforward. The Agency estimates that it will take about 5 hours to prepare this narrative. Based on our experience with this collection, FDA estimates that approximately 10 percent of the respondents with affected applications will submit disclosure statements. Table 2—Estimated Annual Reporting Burden 1
21 CFR section
Number of
                             respondents
Number of
                             responses per 
                             respondent
Total annual
                             responses
Average
                             burden per 
                             response
Total hoursCertification—54.4(a)(1) and (2)—Form FDA 3454
715
1
715
1
715Disclosure—54.4(a)(3)—Form FDA 3455
72
1
72
5
360Total




1,0751
                         There are no capital costs or operating and maintenance costs associated with this collection of information.
 Recordkeeping Burden Under § 54.6 (21 CFR 54.6), the sponsors of covered studies must maintain complete records of compensation agreements with any compensation paid to nonemployee clinical investigators, including information showing any financial interests held by the clinical investigator, for 2 years after the date of approval of the applications. Sponsors of covered studies maintain many records regarding clinical investigators, including protocol agreements and investigator résumés or curriculum vitae. FDA estimates than an average of 15 minutes will be required for each recordkeeper to add this record to the clinical investigators' file. Table 3—Estimated Annual Recordkeeping Burden 1
21 CFR section
Number of
                             recordkeepers
Number of
                             records per 
                             recordkeeper
Total annual
                             records
Average
                             burden per 
                             recordkeeping
Total hours 2Recordkeeping—54.6
715
1
715
0.25
1791
                         There are no capital costs or operating and maintenance costs associated with this collection of information.2
                         Numbers have been rounded.
 Third-Party Disclosure Burden Under § 54.4(b), clinical investigators supply to the sponsor of a covered study financial information sufficient to allow the sponsor to submit complete and accurate certification or disclosure statements. Clinical investigators are accustomed to supplying such information when applying for research grants. Also, most people know the financial holdings of their immediate family, and records of such interests are generally accessible because they are needed for preparing tax records. For these reasons, FDA estimates that the 
                    ( print page 18373)
                    time required for this task may range from 5 to 15 minutes; we used the median, 10 minutes, for the average burden per disclosure (see table 1). Table 4—Estimated Annual Third-Party Disclosure Burden1
21 CFR section
Number of
                             respondents
Number of
                             disclosures per 
                             respondent
Total annual
                             disclosures
Average
                             burden per 
                             disclosure
Total hours 254.4(b)—Clinical Investigators
13,082
1
13,082
0.17
2,2241
                         There are no capital costs or operating and maintenance costs associated with this collection of information.2
                         Numbers have been rounded.
 The burden for this information collection request has changed since the last OMB approval. Our estimated burden for the information collection reflects a 298 hour increase. We have adjusted our estimated burden for the information collection to reflect the number of submissions we received in the last few years. Additionally, for products regulated by the Center for Devices and Radiological Health, we now include De Novo requests as a type of application that may rely on clinical studies. Upon review, we have corrected an inadvertent omission regarding the number of BLAs and BLA efficacy supplements received by our Center for Drug Evaluation and Research and used, in part, as a basis for calculating the cumulative burden estimate. We have corrected that error here, as reflected in table 1. Dated: March 24, 2022. Andi Lipstein Fristedt, Deputy Commissioner for Policy, Legislation, and International Affairs, U.S. Food and Drug Administration.


[FR Doc. 2022-06661 Filed 3-29-22; 8:45 am] BILLING CODE 4164-01-P